Publications by authors named "Zachary A Cooper"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

434,934

Total Likes

15,388

Extended Reach

1,374,630

Social Features

217
E
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Zachary A Cooper, Christine N Spencer

Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
Amanpreet Kaur, Marie R Webster, Katie Marchbank, Reeti Behera, Abibatou Ndoye, Zachary A Cooper

Nature· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.
John Powderly, Martina Imbimbo, Antoine Italiano, Patricia Martin-Romano, Meredith McKean, Zachary A Cooper

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Zachary A Cooper

JAMA Netw Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot Study.
Cibelle Freitas Lima, Auriole Tamegnon, Saxon Rodriguez, Dipen Maru, Philip L Martin, Zachary A Cooper

Pathobiology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma.
Zachary A Cooper, Ying Wang, Philip L Martin, Kosho Murayama, Rakesh Kumar

Discov Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
Neil H Segal, Jeanne Tie, Scott Kopetz, Michel Ducreux, Eric Chen, Zachary A Cooper

Br J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Andrew L Coveler, Matthew J Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas, Zachary A Cooper

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, Subash Baniya, Zachary A Cooper

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.
Luana Guimaraes Sousa, Daniel J McGrail, Felippe Lazar Neto, Kaiyi Li, Mario L Marques-Piubelli, Zachary A Cooper

Clin Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, Zachary A Cooper

Cancer Immunol Immunother· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, Catherine A Shu, Kristen A Marrone, Zachary A Cooper

J Thorac Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Krista Kinneer, Philipp Wortmann, Zachary A Cooper, Niall J Dickinson, Luke Masterson

Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Christopher P Vellano, Michael G White, Miles C Andrews, Manoj Chelvanambi, Russell G Witt, Zachary A Cooper

Nature· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Roy S Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Zachary A Cooper

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Neeta Somaiah, Anthony P Conley, Edwin Roger Parra, Heather Lin, Behrang Amini, Zachary A Cooper

Lancet Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Christopher P Vellano, Michael G White, Miles C Andrews, Manoj Chelvanambi, Russell G Witt, Zachary A Cooper

Nature· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven Lk Ching, Zachary A Cooper

JCI Insight· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.
Fred R Hirsch, Jill Walker, Brandon W Higgs, Zachary A Cooper, Rajiv G Raja

Clin Lung Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma.
Michael G White, Robert Szczepaniak Sloane, Russell G Witt, Alexandre Reuben, Pierre Olivier Gaudreau, Zachary A Cooper

Oncoimmunology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Miles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, Wei-Shen Chen, Zachary A Cooper

Nat Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Ashvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, Prasanta Dutta, Priyamvada Jayaprakash, Zachary A Cooper

Cancer Immunol Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Lillian Siu, Joshua Brody, Shilpa Gupta, Aurélien Marabelle, Antonio Jimeno, Zachary A Cooper

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
Akash Mitra, Miles C Andrews, Whijae Roh, Marianna Petaccia De Macedo, Courtney W Hudgens, Zachary A Cooper

Nat Commun· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis